Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,600.00
-360.00 (-6.04%)
Aug 14, 2025, 3:30 PM KST
-41.61%
Market Cap 537.82B
Revenue (ttm) 10.71B
Net Income (ttm) -14.25B
Shares Out 96.04M
EPS (ttm) -174.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 900,061
Average Volume 868,481
Open 5,760.00
Previous Close 5,960.00
Day's Range 5,580.00 - 5,800.00
52-Week Range 4,325.00 - 11,350.00
Beta 1.02
RSI 42.75
Earnings Date Aug 14, 2025

About Hyundai Bioscience

Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2000
Employees 54
Stock Exchange KOSDAQ
Ticker Symbol 048410
Full Company Profile

Financial Performance

In 2024, Hyundai Bioscience's revenue was 15.05 billion, an increase of 58.73% compared to the previous year's 9.48 billion. Losses were -6.93 billion, -52.21% less than in 2023.

Financial Statements

News

There is no news available yet.